Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs

[1]  G. Sachs,et al.  Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania , 2021, Journal of psychopharmacology.

[2]  B. Lerer,et al.  Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials? , 2020, European Neuropsychopharmacology.

[3]  A. Young,et al.  What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium , 2019, Bipolar disorders.

[4]  G. Remington,et al.  Use of Placebo in Clinical Trials of Psychotropic Medication , 2018, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[5]  J. Howick,et al.  Empirical evidence against placebo controls , 2017, Journal of Medical Ethics.

[6]  M. Ibrahim,et al.  Randomized Controlled Trials: Ethical and Scientific Issues in the Choice of Placebo or Active Control , 2017, Annals of African medicine.

[7]  W. Brown,et al.  Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987‐2013 , 2017, World psychiatry : official journal of the World Psychiatric Association.

[8]  Stuart J Pocock,et al.  The Primary Outcome Fails - What Next? , 2016, The New England journal of medicine.

[9]  A. Young,et al.  Suicide attempts in major depressive episode: evidence from the BRIDGE‐II‐Mix study , 2015, Bipolar disorders.

[10]  E. Vieta,et al.  Risk factors for suicide in schizophrenia: systematic review and clinical recommendations , 2014, Acta psychiatrica Scandinavica.

[11]  Anne Konu,et al.  Drugs foresight 2020: a Delphi expert panel study , 2014, Substance Abuse Treatment, Prevention, and Policy.

[12]  I. Kirsch,et al.  Drug approval and drug effectiveness. , 2014, Annual review of clinical psychology.

[13]  J. Calabrese,et al.  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. , 2013, The American journal of psychiatry.

[14]  C. Barbui,et al.  A New Approach to Psychiatric Drug Approval in Europe , 2013, PLoS medicine.

[15]  N. Cruz,et al.  Head to head comparisons as an alternative to placebo-controlled trials , 2012, European Neuropsychopharmacology.

[16]  E. Vieta,et al.  Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder , 2012, European Neuropsychopharmacology.

[17]  M. Abt,et al.  Issues in the assessment of non‐inferiority: perspectives drawn from case studies , 2011, Pharmaceutical statistics.

[18]  K. Glass,et al.  Substituting placebo for established, effective therapy: Why not? , 2010, Canadian Medical Association Journal.

[19]  S. Garattini,et al.  Ethics in clinical research. , 2009, Journal of hepatology.

[20]  J. Howick.  Questioning the Methodologic Superiority of ‘Placebo’ Over ‘Active’ Controlled Trials , 2009, The American journal of bioethics : AJOB.

[21]  S. Potkin,et al.  What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? , 2008, Schizophrenia bulletin.

[22]  D. Streiner.  The Lesser of 2 Evils: The Ethics of Placebo-Controlled Trials , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[23]  K. Glass.  Ethical Obligations and the Use of Placebo Controls , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[24]  Charles K. Cooper,et al.  Sample size and the ethics of non-inferiority trials , 2005, The Lancet.

[25]  S. Pocock.  The pros and cons of noninferiority trials , 2003, Fundamental & clinical pharmacology.

[26]  P. Czobor,et al.  Placebo or active control trials of antipsychotic drugs? , 2003, Archives of general psychiatry.

[27]  R. D'Agostino,et al.  Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.

[28]  R. Sysko,et al.  Placebo response in studies of major depression: variable, substantial, and growing. , 2002, JAMA.

[29]  S S Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.

[30]  S. Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases , 2000, Annals of Internal Medicine.

[31]  S. Snapinn.  Noninferiority trials , 2000, Current controlled trials in cardiovascular medicine.

[32]  J. Tijssen,et al.  Placebos and placebo effects in medicine: historical overview , 1999, Journal of the Royal Society of Medicine.

[33]  R. Levine,et al.  The need to revise the Declaration of Helsinki. , 1999, The New England journal of medicine.

[34]  D. Streiner.  The Ethics of Placebo-Controlled Trials , 1995, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[35]  Murray Turoff,et al.  The Delphi Method: Techniques and Applications , 1976 .

[36]  N. Dalkey,et al.  An Experimental Application of the Delphi Method to the Use of Experts , 1963 .

[37]  S. Murawiec.  The ultimate need of “precision psychiatry” Interview with Dr Dina Popovic , 2015 .

[38]  Sergio Sismondo,et al.  Industry sponsorship and research outcome. , 2012, The Cochrane database of systematic reviews.

[39]  J. Spławiński,et al.  Clinical trials: active control vs placebo — What is ethical? , 2004, Science and engineering ethics.

[40]  J. Braslow.  David Healy. The Creation of Psychopharmacology , 2004 .